Expert commentary

Announcement:

Schukin Ivan Alexandrovich - candidate of medical sciences, associate professor of the Department of Neurology of the Russian State Medical University, answers the main questions about the drug Mexol®. Why is Mexidol® so widely prescribed and popular among doctors and patients? What pharmacological and clinical effects does it have? What is the evidence base and methods of using the drug Mexidol®? Let's figure it out!

Announcement:

The ischemic process of the heart muscle is the pathogenetic basis of such common diseases as acute myocardial infarction, stable and unstable angina pectoris. An acute or chronic decrease in blood supply to tissues and organs leads to hypoxia and, as a result, energy deficiency, oxidative stress, which may occur irreversible changes in the cell and its death. Understanding the mechanisms of the formation of free radicals became the foundation for creating the concept of combating tissue ischemia and developing a unique domestic drug. Mexidol® is the achievement of the Institute of Pharmacology of the Russian Academy of Medical Sciences. The drug is a combination of two functionally related compounds-3-oxypyridine and succinate. The main pharmacological effects of the drug Mexidol® include antioxidant, antihypoxic and membrane -stabilizing. For many years of clinical use, Mexidol ® has received recognition from the medical community and is rightfully considered the standard of antioxidant cardio and neurocytoprotexts.

Announcement:

Evidence medicine is the principle of clinical practice, which is based on the results of randomized controlled studies, and not individual opinions and ideas of a particular doctor. A randomized controlled study is a method of a scientific and practical medical experiment, in which the studied are randomly divided into groups: some patients fall into an experimental-the main group (for example, therapeutic), while others-into the control (for example, into a group of placebo). Clinical recommendations are currently developed and continued to be developed, which are based on the evidence base and the result of many studies. They help to determine which drug or treatment method is effective in each case. One of the drugs that meet the requirements of evidence -based medicine, and which is included in clinical recommendations in the treatment of a stroke, is Mexidol ^® . The important effects of the drug include antioxidant, antihypoxic and membrane -stabilizing

Announcement:

Original drugs or analogues, what to choose? Why is it worth using the original Mexidol®, not generics? In this video, we will discuss the advantages of the original drug over analogues.

Announcement:

Mexidol® is an original drug, that is, an innovator in his international unauthorized name (MNN segment). It is the first time a synthesized active molecule, which has passed a full cycle of preclinical and clinical studies that proved the effectiveness of Mexidol . Mexidol is based on two related and functionally significant compounds: 2-ethyl-6-methyl-3-hydroxypyridine and succinate. The combination of these components determines the multimodal properties and a wide range of pharmacological effects of the drug Mexidol ® .

Announcement:

There are many terms in the literature to describe a combined pathology. However, the key difference is the presence of a pathogenetic connection between diseases. If several diseases are pathogenetically interconnected, then this is comorbidity. With polymorbidity, the disease can be both pathogenetically or not related - this is a broader concept. It is very important to avoid polypragmasis in the therapy of comborbid patients, for this we need to optimize the drug therapy scheme, as well as the use of multimodal drugs. 

Announcement:

It was previously believed that rehabilitation after a stroke should be delayed for several days or weeks in order not to harm the patient. But recent studies have shown that rehabilitation must begin from the first hours in order to avoid severe complications, such as non -class syndrome, muscle spasticism, pain syndromes, psychoemotional and cognitive disorders. Rehabilitation is based on two principles - a multidisciplinary approach to the consequences of a stroke and timely medical support in order to form adequate intersneal ties - one of the main criteria of neuroplasticity.

Announcement:

The consequences and complications of stroke can be much more dangerous than the stroke itself, so it is important to provide patients with qualified and timely assistance. One of the main factors of successful rehabilitation after a stroke is its early timely beginning, including drug therapy using neurocytoprotective drugs. After a stroke, Mexidol® helps to improve cerebral metabolism, microcirculation, rheological properties of blood, reduces platelet aggregation, has a hypolipidemic effect.

Announcement:

During the pandemic Covid-19, the mortality of the stroke increased. The development of a stroke in patients with Covid-19 may be associated with various risk factors such as arterial hypertension and atherosclerosis. The virus can also lead to a cytokine storm and a systemic inflammatory response, which contributes to the development of ischemic stroke. Hemorrhagic stroke is more often associated with Covid-associated coagulopathy and erythrocyte hemolysis. Patients with a stroke who suffered Covid-19 often need constant help in everyday life. The structure of assistance to these patients has not changed, but new clinical methods were developed to conduct these patients. The intake of Mexidol® after coronavirus has the following effects: membrane, antihypoxic, antioxidant, etc. Read more about the effects, as well as taking the drug Mexidol® after a stroke and therapy after Covid-19 in our video.

Announcement:

Medicine is an area that is constantly changing and developing. What was evidence 10 or 15 years ago may not be so relevant today. Requirements for confirmation of the effectiveness and safety of treatment methods, including pharmacotherapy, according to the principles of evidence -based medicine, become more and more strict. We need research that meet certain standards and are carried out on a large number of patients. The proof of the vascular nature of cognitive disorders, treatment protocols and drugs should be based on international-recognized criteria. Based on these criteria, the results of the study of the drug Mexidol® for the effectiveness of chronic brain ischemia are presented.

Announcement:

Mexidol ® is a well -known drug with proven effectiveness, which with prolonged therapy helps patients return to active life. In the study of the drug Mexidol® Epica, a clinical assessment of the effectiveness and safety of the drug in patients with ischemic stroke was carried out.

Announcement:

Age is a relative concept. In the last century, the age of 60 years seemed already deep old age. Currently, patients are 70+, even 80+, is not uncommon at the doctor. Cognitive disorders can be a sign of serious diseases and require attention from the doctor. Diagnosis of cognitive disorders should begin in the early stages . Mexidol® in old age is an effective and safe drug. The video presents diagnostic methods and the principles of cognitive disorders in patients are disclosed.

Announcement:

It is impossible to prevent a traumatic brain injury. Moreover, the incidence remains very high. A frequent complication after a traumatic brain injury is postcommunication syndrome. Most often, such patients complain of a decrease in concentration of attention, as well as a violation of memory. The use of neurocytoprotectors, as one of the most promising groups of drugs for the treatment of neurological diseases, allows you to effectively support patients with traumatic brain injury. Mexidol®, with traumatic brain injury, stops oxidative stress and helps to normalize the metabolism of the brain.

Announcement:

Proper nutrition and mental loads are the key to maintaining brain activity. Often we ask ourselves - “How to preserve our mental abilities throughout life?” On the one hand, there are people who need notes and the help of others, so as not to forget the simplest things. On the other hand, there are those who, even in a very old age, have excellent memory and clear thinking without any difficulties. So is it possible to maintain sharpness of the mind throughout life? Certainly! To do this, you need to fulfill certain rules and train your brain. In this video, we have collected useful tips and practical recommendations for preserving and improving memory, intelligence and concentration, as well as answers to questions on the use of Mexidol®.

Announcement:

At the moment, it is proved that the main symptom of chronic brain ischemia is cognitive disorders. This symptom is the main one for both the doctor and the patient. For the patient, because it is cognitive disorders that worsen the quality of life, but for the doctor, because this is the main guideline in the diagnosis. As pathogenetic therapy, Mexidol® is often recommended. Mexidol® has an anti -amnestic effect for memory and attention and has a pronounced ability to improve the processes of higher nervous activity. The effectiveness of the drug with brain ischemia, cognitive disorders, anxiety disorders, etc. has been proved.

Announcement:

Memory disorders are a common problem of elderly people. Often such disorders are associated with cerebrovascular damage to the brain and concomitant diseases. Patients not only lose the ability to remember information, but also experience anxiety, decreased mood and other symptoms. In this video, we will talk about the causes of memory impairment, as well as how to choose the right drug for therapy, why Mexidol® has a pronounced ability to improve memorization processes, how Mexidol® acts with depression.

Announcement:

Chronic brain ischemia is a pathology characterized by the inconsistency between the blood supply to the brain tissue and its need for oxygen and nutrients. This condition can occur against the background of atherosclerosis of the vessels of the brain and the stenosis process, against the background of microangiopathy for hypertension. Endothelial dysfunction, neurogenic inflammation, oxidative stress - all this leads to the fact that tissue blood supply is not adequate enough. And it is necessary to choose a drug that would act on all these links of pathogenesis. The drug Mexidol ® is the same drug of choice, because it has an antihypoxic, antioxidant and membraneoprotective effect. It affects vascular risk factors, on hyperglycemia, to arterial hypertension to some extent. The drug has nootropic, anxiolytic and anti -alert effect, normalizes sleep. Also, the drug has a heroome effect. Mexidol ® is a drug of choice for the treatment of chronic brain ischemia.

Announcement:

Glaucoma is a quiet killer of the optic nerve. The main danger of glaucoma is that often its course is imperceptible to the patient and can progress without impaired intraocular pressure. The second terrible disease is age -related macular degeneration. It affects the center of the macula in the retina responsible for clear vision. Glaucoma and macular degeneration of the retina are two diseases that can lead to blindness. To preserve visual functions in these diseases, it is very important to carry out retinoprotection - retinal protection. Mexidol ®, with glaucoma and other lesions of the optic nerve, showed high efficiency as a neurocytoprotector.

Announcement:

Glaucoma is a disease in which intraocular pressure increases. This leads to damage to the optic nerve and loss of vision. However, do not despair! Early diagnosis, correct therapy and the use of neurocytoprotexts can prevent vision loss. The role of hypoxia, chemical disorders and oxidative stress in the pathogenesis of glaucoma is undeniable. But what place does neurocytoprotectors occupy in patients with glaucoma? Studies show that neurocytoprotectors play an important role in preserving visual functions in patients with this disease. They help maintain the survival of the ganglion cells of the retina and slow down the degeneration of the optic nerve. One of the trusted neurocytoprotectors is Mexidol®. Studies of the drug Mexidol® confirm its high efficiency in the fight against glaucoma and other diseases of the optic nerve.

Announcement:

The main goal of the treatment of glaucoma is to preserve visual functions and quality of life of the patient with an adequate cost of treatment. Neuroprotection is a very important aspect in preserving visual functions in patients with glaucoma. The studies have demonstrated the results of the effectiveness and safety of the drug Mexidol® in patients with primary open-angle glaucoma of the I-III stage.

Announcement:

About 2 million people per year dies from alcohol. Alcoholism carries not only a violation of the function of the central nervous system, but also metabolic changes in the whole organism. Therefore, in the complex therapy of patients with alcoholic withdrawal, not only drugs affecting the neurotransmitter balance are used, but also drugs of the antioxidant and anti -hyphyxant group. One of the classic examples of such drugs is Mexidol®. This drug significantly improves the overall health of patients, restores their cognitive functions: memory and attention. Mexidol® with a hangover relieves headache, nausea and dizziness.

Announcement:

Alcoholic withdrawal syndrome - a person’s condition after prolonged use of alcoholic beverages. It is characterized by a neurotransmitter storm and can lead to serious physical and mental disorders. Apistenic syndrome causes complications, such as heart rhythm and cerebral circulation disorders. Therefore, it is important to seek medical help as soon as possible. Early treatment will prevent complications and begin effective treatment. For example, the drug Mexidol® during withdrawal is able to reduce the manifestation of intoxication, stop headaches, reduce the harmful effects of alcohol. A number of studies of the drug confirm its effectiveness and favorable effects.

Announcement:

The brain is one of the main target organs of arterial hypertension. The most common cerebral symptoms of arterial hypertension should include headaches mainly in the nape area, as a rule, in the morning, dizziness of varying degrees of severity, noise in the ears and visual impairment. Mexidol® is a drug that has an evidence base and is effective for patients with arterial hypertension.

Announcement:

Increased blood pressure is the main factor of high risk of premature death, brain stroke, myocardial infarction and other cardiovascular complications.

The most vulnerable blending organ with arterial hypertension is the brain.

The clinical manifestation of brain damage as an organ-target of arterial hypertension is cognitive impairment-such as impaired memory and attention. Thus, cognitive disorders are due to the manifestation of hypertension. To optimize antihypertensive therapy, in addition to basic drugs, neurometabolic drugs must be included in therapy and it is advisable to choose those that, as part of one tablet, realize several effects. Such a drug is Mexidol ® . It has a membranestabilizing and antioxidant effect, and also improves brain perfusion, which is extremely important for arterial hypertension. Proper basic therapy and the correct additional drug with a multimodal action mechanism provide maximum improvement in cognitive functions, and, therefore, the quality of life of patients.

Announcement:

Hypertension is the main risk factor for the development of hemorrhagic and ischemic stroke. In addition, this is one of the strongest risk factors for the development of cognitive disorders. Neurocytoprotective therapy is a whole direction in neurology, which uses various drugs to protect the brain. How to choose the right neurocytoprotector? It is important to pay attention to its mechanism of action. An ideal drug should have a polymodal effect, that is, to affect various processes associated with brain damage. One of these drugs is Mexidol ® . In this video, experts will talk about the use of Mexidol®, why Mexidol® with hypertension, this is an important level of treatment.

Announcement:

The syndrome of the vertebral artery, or spa is a serious pathology in which the blood flow in the vertebral artery is disturbed due to various causes (in particular, due to osteochondrosis of the cervical spine), and manifested by dizziness, impaired coordination of movement, double-eye in the eyes, etc. The same brain ischemia (discirculatory encephalopathy), but associated with degenerative diseases in the spine. It is extremely important to prevent the progression of the condition and choose effective comprehensive treatment, including drug and non -human therapy.

Announcement:

Therapists often encounter such diseases and conditions that are named “vertebral artery syndrome”, “dorsopathy”, “vertebrobasicular failure”. In the clinical picture, a combination of autonomic and ischemic symptoms is observed, which is manifested by dizziness, double in the eyes, and dissection. It is very important to distinguish and share these complaints. In case of suspicion of vertebro-baslar failure, it is necessary to conduct differential diagnosis with other diseases that can lead to pathology of the vertebral artery. To facilitate the well -being of the patient and the normalization of blood circulation, Mexidol® is often prescribed. Mexidol® in dizziness affects multimodally and provides improvement in the quality of life.

Announcement:

How is aging? What processes are performed at this moment? Science had no answer to these questions for a long time. However, with the advent of the theory of Inflaiming, we approached the explanation of this phenomenon. According to this theory, the aging process and the development of geriatric syndromes are associated with the progression of chronic, aseptic inflammation. This process is aggravated by oxidative stress, which is one of the main causes of inflammation. And here pharmacological and non -pharmacological methods come to the rescue. The drug Mexidol ® was investigated in laboratory tests that showed its ability to extend life. Mexidol® Effect : antioxidant, antihyplance and membranes.

Announcement:

The free-radical theory of aging explains the violation of the balance in pro- and antioxidant systems, which leads to mitochondrial dysfunction and early aging. Experimental studies with animals have shown that Mexidol ® activates mitochondrial functioning processes and eliminates mitochondrial dysfunction. This leads to results such as an increase in the life expectancy of animals and normalizing their behavioral reactions. Accordingly, taking Mexidol® in old age is able to improve the quality and lifespan.

Announcement:

What is polyprahmasia? The simultaneous use of several drugs for the treatment of a certain disease is called polypragmasia. Unfortunately, such a phenomenon has certain risks: undesirable reactions of the body, complications of treatment and low adherence to patients to therapy. The use of multimodal drugs is one of the possible solutions to the problem of polypragmasis. Such drugs have the ability to affect not only one, but on several causes of the development of the disease. One of these funds is Mexidol®. Mexidol® Efficiency has been proven by many studies, and its effect has multimodal properties.

Announcement:

Comorbid patient is a patient who is faced with a doctor of almost any specialty. Such patients differ in the presence of several chronic diseases at once. Especially often comorbid patients are found among the elderly. A classic example of such a patient is a patient with metabolic syndrome. It combines several conditions, including arterial hypertension, obesity, dyslipidemia and diabetes. The patient’s brain with metabolic syndrome is especially susceptible to pathological processes. Therefore, one of the main tasks of doctors is the protection of this neuronal structure. Mexidol® often becomes an assistant in solving this problem. The use of Mexidol® for ischemia , hypertension and other diseases contributes to the prevention of complications.

Announcement:

Patients with the diagnosis of COVID-19 require special attention and the multicomponent process of conducting, the basis of which is the timely and adequate use of drug treatment and rehabilitation. Covid-19 can be associated with such lesions of the central and peripheral nervous system as, for example, encephalitis, meningitis, leukoencephalopathy and Guine - Barre syndrome. The quality of the patient’s recovery depends on the correct rehabilitation. Mexidol ® after coronavirus is an integral part of patient therapy with the consequences of a new infection.

Announcement:

Oxidative stress and energy deficiency are the main mechanisms of pathogenesis of neurological disorders after coronaviral infection. Therefore, for patients who have undergone Covid-19, antioxidants, antihypoxants and energy corruption are needed. Mexidol ® is a pathogenetically justified remedy that helps treat neurological disorders. Mexidol® after coronavirus , as a result of the restoration of the energy synthetic function of mitochondria and neutralization of oxidative stress in nervous tissue, reduces the severity of asthenia, improves sleep and cognitive functions. Studies of the drug Mexidol® have shown that it also reduces the symptoms of chronic brain ischemia, improving the quality of life of patients who have undergone coronavirus infection.

Announcement:

Many adult diseases begin in childhood. Attention deficiency syndrome (ADHD) is a disorder that is characterized by inattention, hyperactivity and impulsiveness and can be caused by various factors, including genetic, perinatal and psychological. In the treatment of ADHD in children, psychological correction, psychotherapy and nootropic drugs are used. One of these drugs with a high security profile is Mexidol ® . In clinical studies, Mexidol ® showed high efficiency and safety in the treatment of children with attention deficiency syndrome, as a result of which an improvement in cognitive functions, antiasthenic effects and normalization of vegetative functions were achieved.

Announcement:

The syndrome of attention deficit and hyperactivity (ADHD) is a common clinical disorder in children and can manifest itself in the form of impaired attention, manifestations of hyperactivity and impulsiveness. ADHD should be differentiated with other conditions, such as behavior disorder, anxiety disorders, separation anxiety, social alarm and others. ADHD has a complex pathogenesis associated with genetic and biological factors. The approach to treatment requires an interdisciplinary assessment and should include safe drugs aimed at reducing oxidant stress and protecting brain cells from free radicals. Drug treatment using the drug Mexidol® showed high effectiveness in the treatment of ADHD in children.

Announcement:

In the new issue of the Neurology Plus program, Professor Anatoly Ivanovich Fedin and a corresponding member of the Russian Academy of Sciences, Professor Natalya Aleksandrovna Suponeva consider modern approaches to rehabilitation after stroke and prevention of repeated cases, including pharmacological support.

The relevance of the discussion is due to the fact that each 4th stroke is repeated, and 60% of patients become disabled, but early rehabilitation significantly improves the prognosis.

The key aspects of rehabilitation include:

• Early beginning-the first 3-6 months are critical for recovery.
• Multidisciplinary approach - a team of doctors, kinesitherapists, speech therapists and psychologists.
• Technologies: robotic mechanotherapy, transcranial magnetic stimulation, exoskeletons.

The prevention of re -stroke includes control of blood pressure (target values ​​are individual), antitrombotic therapy (aspirin, clopidogrel), statins for hyperlipidemia, anticoagulants for patients with atrial fibrillation.

Conclusion: complex rehabilitation + individual prevention = maximum restoration and reduction in the risk of re -stroke.

Announcement:

As part of the “Interdisciplinary Academy. Neurology” series, a round table was held on current issues of ischemic stroke.

Key topics for discussion:

• Pathogenesis of stroke – the role of oxidative stress, mitochondrial dysfunction and neurodegenerative processes;
• Diagnosis and prognosis – risk factors, severity markers and rehabilitation options;
• Modern approaches to therapy – the effectiveness of neuroprotective strategies, including the use of Mexidol (proven effect on antioxidant protection and restoration of energy metabolism).

Practical conclusions:

• The importance of early diagnosis and prevention: control of blood pressure, diabetes, depression and venous insufficiency;
• Early diagnosis of chronic ischemia is the key to preventing stroke;
• The role of biochemical markers in predicting the course of stroke;
• Optimal treatment regimens to improve patients' quality of life.

Find out how brain biochemistry influences stroke prognosis and which methods are already changing clinical practice today! Watch the full recording of the roundtable to stay up to date!

Announcement:

In the webinar, experts discuss modern approaches to rehabilitation after a stroke and consider such issues as:

• Neuroplasticity – how the brain recovers from damage;
• The role of pharmacotherapy – how Mexidol (ethylmethylhydroxypyridine succinate) improves functional recovery and reduces the effects of ischemia;
• Neglect syndrome - how to recognize and correct it in time;
• Multidisciplinary rehabilitation is a combination of drug and non-drug methods (occupational therapy, exercise therapy, psychocorrection).

Key takeaway: Mexidol is one of the most effective neuroprotectors, confirmed by clinical studies, including improvement of motor functions, cognitive recovery and quality of life of patients.

Although the focus is on antidepressants, it is emphasized that drugs with neuroprotective action (such as Mexidol) also affect BDNF (brain-derived neurotrophic factor), improving recovery.

Watch the full recording for details!

Announcement:

Arterial hypertension (AH) is a global problem, “getting younger” and affecting people regardless of social status. Primary care physicians often face late diagnosis, and patients – consequences: from cognitive impairment to dementia.

Key topics:

• Diagnosis of hypertension: ABPM (daily blood pressure monitoring) is the gold standard;
• Patient profile: obesity, diabetes, stress – “red flags”. Young patients at risk;
• Target organ No. 1 – the brain: how hypertension destroys cognitive functions (memory, attention, speed of thinking) and increases the risk of stroke;
• The role of the therapist: achieving target blood pressure, early screening of cognitive impairment (tests: Montreal Scale, Trail Making Test).

Therapy:

• Basis: ACE inhibitors/sartans + calcium antagonists/diuretics.
• Neuroprotection: Mexidol is a multimodal drug with proven efficacy (MEMO study).

Early diagnosis and a comprehensive approach save the brain and quality of life of patients!

Announcement:

Key topics for discussion:

Key topics for discussion:

• Relevance of the problem and statistics;
• Definition of biomarkers and their importance;
• Promising biomarkers;
• The future lies in omics technologies (proteomics, metabolomics), which allow the analysis of thousands of molecules for personalized therapy;
• Clinical applications (neuroprotection and targeted therapy).

Biomarkers are the key to accurate diagnosis and personalized treatment of stroke!

Announcement:

As part of the cycle "Interdisciplinary Academy. Neurology" a round table was held dedicated to current issues of arterial hypertension. Experts - Professor Vadim Vitalievich Tyrenko and Professor Evgeniya Viktorovna Ekusheva - analyze the key problem: how arterial hypertension destroys the brain and leads to cognitive impairment.

What you will learn from the video:

• Hidden threats: why “silent” infarctions and leukoaraiosis are detected only by MRI;
• Early Symptoms: How to Recognize Cognitive Impairment Before Dementia Develops;
• Treatment Errors: Why Blood Pressure Control Isn't Enough to Protect the Brain;
• Neuroprotection: clinical data on drugs with proven efficacy (including Mexidol);
• Advice from a cardiologist: which antihypertensive drugs best protect the blood vessels of the brain.

Watch the full analysis with evidence and clinical cases!

Announcement:

The new episode of the program “Dialogue with Experts” discusses the current problem of arterial hypertension (AH) and its impact on the body.

Main topics:

• Hypertension is a global problem, despite the arsenal of drugs.
• Early signs of brain damage in hypertension: cognitive impairment, fatigue, distracted attention.
• Modern methods of diagnosing cognitive disorders (Montreal scale, attention tests).
• "Roadmap" of a patient with arterial hypertension. Criteria for resistant hypertension.
• Treatment strategies: combination treatment, importance of neuroprotection.
• The role of Mexidol in brain protection: results of the MEMO study, safety and efficacy.
• An integrated approach: not only pressure control, but also protection of target organs.

Announcement:

In this lecture, Professor Elena Anatolyevna Katunina examines key aspects of post-stroke disorders, including movement disorders (hemiparesis, spasticity, apraxia) and cognitive dysfunctions (dementia, neglect syndrome). The lecturer provides statistics, explains the mechanisms of pathology development and offers rehabilitation methods.

Main topics of the lecture:

• Stroke and its consequences – why do only 10-20% of patients return to their previous lives?
• Movement disorders – from classic hemiparesis to rare syndromes (for example, “alien hand”).
• Cognitive impairment – how does stroke affect memory, attention and thinking?
• Diagnostics and rehabilitation – what tests detect apraxia and neglect syndrome?
• Treatment – the role of neuroprotective therapy (Mexidol) in recovery.

Key takeaway: Stroke is not only an acute episode but also a long-term rehabilitation process that requires a comprehensive approach to motor and cognitive impairment.

Rehabilitation after an insult: what a therapist needs to know

Announcement:

The lecture examines key aspects of post-stroke rehabilitation that are relevant for primary care physicians.

Key points:

• Epidemiology: In Russia, > 130 thousand strokes are registered annually, 90% of which are ischemic. Up to 85% of patients experience movement disorders, speech disorders and cognitive deficits.
• Economic burden: the cost of treating one case reaches 1–1.5 million rubles, including long-term care and loss of ability to work.
• The main risk factors: arterial hypertension, atherosclerosis, diabetes mellitus, obesity and smoking are the key triggers of atherothrombotic and lacunar strokes.

Modern approaches to rehabilitation:

• Three-stage model:
  • Stage 1: Early rehabilitation in hospital (first 21 days).
  • Stage 2: specialized centers (up to 3-6 months).
  • Stage 3: Outpatient observation (up to 12 months).
• The role of drug therapy: the drug Mexidol (ethylmethylhydroxypyridine succinate)
  • Improves the restoration of neurological functions.
  • Reduces the risk of recurrent stroke by 5 times in patients with hypertension.
  • Corrects cognitive and emotional disorders (depression, anxiety).
• Practical recommendations:
  • Scheme of application of Mexidol:
    • 14 days intravenously at 500 mg/day → 2 months orally (Mexidol Forte 250 mg × 3 times a day).
    • Optimally, 2 courses per year.
• The Importance of a Multidisciplinary Approach: Combination of Medication, Physical Rehabilitation and Psychological Support.

Rehabilitation after an insult: what a therapist needs to know

Announcement:

Mexidol ® is the key to protecting and restoring the brain during ischemia!

The brain is extremely sensitive to oxygen deficiency — after just 30 minutes of hypoxia, irreversible damage to neurons begins due to energy deficiency and the toxic effects of free radicals. Mexidol ® , which combines ethylmethylhydroxypyridine and succinate, effectively restores energy metabolism in mitochondria, reduces the level of oxidative stress and blocks the cascade of ischemic processes. Due to its ability to penetrate nerve cells and stimulate defense mechanisms, Mexidol ® improves cerebral circulation and neuroregeneration, increasing the chances of maintaining health and brain function in vascular diseases.

Announcement:

Vision is one of the most important senses, but many eye diseases develop unnoticed, leading to irreversible consequences. In this episode of the program "Interdisciplinary Academy. Neurology", leading experts in the field of ophthalmology and neurology - Evgeniya Viktorovna Yekusheva and Evgeny Alekseevich Egorov - discuss two key pathologies - glaucoma and age-related macular degeneration (AMD).

Glaucoma: "The silent thief of sight"

• Why can glaucoma develop even with normal intraocular pressure?
• How do vascular disorders (hypertension, diabetes) accelerate optic nerve damage?
• The danger of angle-closure glaucoma: how not to miss an acute attack?
• Modern treatment methods range from antihypertensive drops to laser surgery.

Age-related macular degeneration (AMD): how to preserve central vision?

• Why is AMD the leading cause of blindness in people over 60?
• What is the difference between the "dry" and "wet" forms and how are they treated?
• The Role of Lutein and Antioxidants: Why Should You Take Them Regularly?
• New methods of therapy - intravitreal injections and hardware treatment.

The relationship between eye and neurological diseases

• How can changes in the fundus indicate cerebrovascular pathologies?
• Why should neurologists and ophthalmologists work together?
• Mexidol and neuroprotection: what drugs help protect vision?

This issue will be especially useful for doctors - ophthalmologists, neurologists, therapists - to understand the relationship between systemic diseases and eye pathology.

Key Takeaway: Early detection and a comprehensive approach can prevent blindness! Don't miss the important details - watch the full analysis in the video.

Announcement:

In this issue, experts in the field of geriatrics and neurology - Nadezhda Konstantinovna Runikhina and Elen Araikovna Mkhitaryan - examine key aspects of managing elderly patients:

• Senile asthenia - why does 1 in 6 elderly people lose independence and how to prevent it?
• Arterial hypertension - why is pressure 140/90 mm Hg safer than 120/80 for patients 80+?
• Cognitive impairments - how to distinguish normal aging from pathology? Simple tests for primary screening.
• Polypharmacy - why "the fewer drugs, the better" and how to choose evidence-based therapy (using the drug Mexidol as an example).
• Falls and leukoaraiosis: how is white matter damage linked to fracture risk?

For whom:

✔ General practitioners, neurologists, cardiologists - how to adapt treatment for older patients.

Key takeaway: Modern geriatrics is not just about treating diseases, but about maintaining the patient's independence and functionality. Watch the full video breakdown!

Announcement:

What is this teleseminar about?

Anxiety disorders are not just “nerves” or temporary stress. They change the body’s biochemistry, accelerate the development of chronic diseases and shorten life. In this interdisciplinary teleseminar, leading specialists Evgeny Sergeevich Kurasov and Veronika Nikolaevna Shishkova analyze why anxiety and depression are becoming one of the key risk factors in modern medicine.

Key topics:

Anxiety as a modifiable risk factor

• Why did the European Society of Cardiology include anxiety and depression in clinical guidelines?
• How psychoemotional disorders worsen the prognosis for hypertension, coronary heart disease and diabetes.

The COVID-19 Pandemic and the Explosion of Anxiety Disorders

• Why do even mild forms of Covid cause long-term cognitive and emotional impairment?
• Post-Covid syndrome: how to distinguish neurological symptoms from psychiatric ones?

Somatic masks of anxiety

• Panic attacks vs. heart attack: how not to miss the threat?
• Dizziness, tachycardia, insomnia - when it is not the disease but the psyche that is to blame?

Diagnosis and treatment: what can a therapist do?

• Simple scales for identifying anxiety (GAD-7) - how to use them in routine practice.
• Why are benzodiazepines not the answer, and antidepressants not always?
• Drugs with a high safety profile (including Mexidol) - when, to whom and how.

Joint work of a psychiatrist and an internist

• How not to go too far: the balance between somatic and psychiatric treatment.
• Real cases from practice: patients with hypertension and panic attacks.

Who is this teleseminar for?

• Doctors (therapists, cardiologists, neurologists) - to more effectively help patients with “unexplained” symptoms.
• Psychologists and psychotherapists - to understand the somatic consequences of anxiety.

What will you learn?

• How to recognize an anxiety disorder in a patient complaining of “heart pain” or “constant fatigue.”
• What non-drug methods (rational psychotherapy, patient schools) work in primary care?
• Why anxiety treatment is not just about pills, but also about lifestyle changes.

This is a lively dialogue between two experts with examples from clinical practice, analysis of diagnostic scales and modern therapy protocols.

Watch to understand how the mind and body influence each other - and how to help yourself or your patients!

Announcement:

What is this teleseminar about?

Alcoholism is not just a bad habit, but a chronic disease that destroys the brain, provokes depression, anxiety and leads to severe somatic complications. In this interdisciplinary teleseminar, leading specialists Evgeniya Viktorovna Yekusheva and Evgeny Sergeevich Kurasov analyze:

• Why does alcoholism often go undiagnosed in general medical practice?
• How to distinguish between everyday drunkenness and a developed addiction?
• Why do anxiety and depression lead to alcoholism, and alcoholism to depression?
• What irreversible changes occur in the brain with long-term abuse?
• How has COVID-19 affected the rise in alcohol use disorders?

Key topics:

Alcohol and the psyche

• Why do 50% of patients with anxiety disorders abuse alcohol?
• How Alcohol Masks Depression and Increases Suicide Risk.

Diagnostics: How to recognize addiction?

• Early signs: "Monday" absences from work, tremors, sweating.
• Why patients hide the problem and how to ask the right questions.

Withdrawal syndrome: from tremors to delirium tremens

• The dangers of abruptly stopping drinking alcohol.
• Why Benzodiazepines Are the Gold Standard for Withdrawal Management.

Brain damage and cognitive impairment

• Alcoholic dementia, Wernicke-Korsakoff encephalopathy: is it possible to restore the brain?
• How alcohol accelerates the development of stroke and neurodegenerative diseases.

Treatment: What Really Works?

• Why don’t IVs and “coding” solve the problem?
• The role of the drug Mexidol in reducing hypoxia and autonomic disorders during withdrawal.
• Psychotherapy vs. Total Abstinence: Which Approaches Are Effective?

Who is this teleseminar for?

• Doctors (therapists, neurologists, cardiologists) - to recognize alcohol addiction in time in patients with “unexplained” symptoms.
• Psychologists and psychotherapists - to understand the biological mechanisms of addiction.

What will you learn?

• How to distinguish alcohol withdrawal from a panic attack.
• Why there are no "safe doses of alcohol."
• What drug therapy can be used in general practice.

This is a live dialogue between experts with analysis of clinical cases, MRI data and practical recommendations for therapy.

Announcement:

What is this video about?

Glaucoma is one of the most insidious and socially significant diseases leading to irreversible blindness. Despite its prevalence, many patients and even doctors underestimate its danger. In this video, leading experts in the field of neurology and ophthalmology - Evgeniya Viktorovna Yekusheva and Ilmira Rifovna Gazizova - analyze glaucoma not only as an eye disease, but also as a systemic neurodegenerative disease.

Key topics for discussion:

Glaucoma is more than just an eye pressure problem

• Why is glaucoma considered a neurodegenerative disease?
• How is optic nerve damage related to changes in the brain?
• Open-angle and closed-angle glaucoma: what is the fundamental difference?

Why is glaucoma so often missed?

• Asymptomatic course: how a patient can lose vision without noticing anything.
• Acute attack of glaucoma: how to distinguish it from migraine or hypertensive crisis?
• Key symptoms that should alert a doctor of any specialty.

Glaucoma and systemic diseases

• Link to hypertension, diabetes, atherosclerosis: how vascular pathologies accelerate vision loss.
• Why should patients with diabetes have regular eye exams?
• How does chronic cerebral ischemia affect the progression of glaucoma?

Modern diagnostic methods

• Optical coherence tomography (OCT) and other optic nerve imaging technologies.
• Why is measuring intraocular pressure not enough?
• How does neuroimaging (MRI, PET-CT) help in assessing brain damage in glaucoma?

Treatment: from antihypertensive therapy to neuroprotection

• Is it possible to stop the progression of glaucoma?
• The role of drugs with neuroprotective action (using the drug Mexidol as an example).
• Why an interdisciplinary approach is important: joint work of an ophthalmologist, neurologist and therapist.

Practical recommendations for doctors

• Which patient groups are at high risk?
• Is it possible to preserve vision if glaucoma has already been diagnosed?

Who is this video for?

• Doctors (ophthalmologists, neurologists, therapists, endocrinologists) who want to better understand the pathogenesis of glaucoma and modern approaches to treatment.

Why is it worth watching?

• Expert level: speakers are practicing specialists with extensive clinical experience.
• Latest data: an analysis of the latest research and clinical guidelines.
• Practical benefits: clear diagnostic and treatment algorithms that can be applied in work.

Don't miss the opportunity to learn how modern medicine is fighting one of the main causes of blindness!

Announcement:

What is this video about?

A modern patient with arterial hypertension, obesity and diabetes is not only a classic "cardiological case", but also a person with a high risk of cognitive and psycho-emotional disorders. In this video, Professor Veronika Nikolaevna Shishkova analyzes:

• Why do metabolic syndrome and chronic stress lead not only to heart attacks, but also to memory loss, anxiety and depression?
• How does hypertension damage the brain and accelerate the development of dementia?
• Why do 56% of cardiac patients already have mild cognitive impairment?
• How has Mexidol demonstrated its effectiveness in improving cognitive function and reducing anxiety?

Why is this important?

For doctors:

• Learn how to identify cognitive impairment in patients with hypertension and coronary heart disease.
• Understand why standard antihypertensive therapy is not enough.
• You will see research data on the neuroprotective effect of the drug Mexidol.

Key findings:

• Hypertension is a risk factor for dementia.
• 56% of cardiac patients in the study had cognitive impairment, 15% had signs of dementia.
• How the drug Mexidol, when prescribed consistently, improves memory, reduces anxiety and improves quality of life.

Who is this video for?

• Cardiologists, therapists, neurologists - how to work with "concomitant" cognitive impairments.
• Anyone interested in the connection between the heart, blood vessels and brain.

Watch to understand: why hypertension treatment is not only about taking “blood pressure” pills, but also about taking care of your brain!

Announcement:

Traumatic brain injury (TBI) is one of the most common causes of disability, especially among young people. In this video, experts in the field of neurology and psychiatry - Kamchatnov Pavel Rudolfovich and Kurasov Evgeny Sergeevich - analyze:

• Why can even a mild TBI lead to serious consequences?
• How to distinguish a concussion from a bruise without neuroimaging?
• Why do more than half of patients with TBI have cognitive impairment?
• How does trauma trigger neurodegeneration?
• The drug Mexidol in the treatment of TBI.

Key points:

• Two critical ages for TBI are children under 5 years of age and the elderly over 75.
• The main symptoms of mild TBI are loss of consciousness, headache, amnesia (patients often hide or exaggerate symptoms).
• Dangerous signs are bradycardia and hypertension (Kushenko's symptom, indicating damage to the brain stem).
• Late effects: Patients with TBI have a 2-fold higher risk of dementia, even if the injury was mild.
• The drug Mexidol reduces cerebral edema and accelerates recovery when administered consistently.

Who is this video for?

• Neurologists - diagnostics, management of patients with TBI.
• Psychiatrists - post-traumatic disorders (anxiety, depression, psychosis).
• General practitioners/traumatologists - when to refer to a neurologist?

Watch to understand:

• Why does a “minor” injury not mean “safe”?
• How Mexidol helps with TBI.
• What to do if memory loss or anxiety occurs after an injury?

Don't miss important information about TBI - watch the video!

Announcement:

Chronic cerebrovascular diseases, especially against the background of metabolic syndrome and diabetes mellitus, are one of the key problems of modern medicine. In this video, leading specialists Evgeniya Viktorovna Yekusheva and Veronika Nikolaevna Shishkova analyze pathogenesis, diagnostics and modern approaches to therapy, paying special attention to the role of obesity, insulin resistance and cognitive impairment.

Main topics:

• Relevance of the problem: metabolic syndrome (obesity, hypertension, diabetes) is a key risk factor for chronic brain damage. Every fourth person in developed countries suffers from it, and forecasts indicate a 50% increase in cases in the next 20 years.
• Pathogenesis: Systemic inflammation, insulin resistance and endothelial dysfunction lead to microangiopathy, lacunar infarctions and cognitive impairment. Neurological disorders are detected in 95% of obese patients.
• The role of obesity: abdominal obesity is a risk marker even with a normal BMI. An increase in waist circumference by 1 cm increases the likelihood of cardiovascular complications.
• Cognitive impairment: the tip of the iceberg of cerebrovascular pathology. Manifested by a decrease in memory, executive functions and psychomotor speed, but often remains underestimated.
• Therapy:

• Non-pharmacological methods: physical activity and lifestyle modification are critical.
• Pharmacological support: Mexidol is a drug with proven effectiveness in improving cognitive functions, reducing insulin resistance and normalizing the lipid profile. Consistent therapy with the drug demonstrates stable positive effects.

Key findings:

• Early diagnosis of metabolic disorders and cognitive deficits can slow the progression of diseases.
• An integrated approach (correction of risk factors + drug therapy) is the gold standard for patient care.

For whom: neurologists, therapists, cardiologists, endocrinologists and doctors of related specialties.

Announcement:

Glaucoma remains one of the most complex problems in ophthalmology, where traditional reduction of intraocular pressure is often insufficient to preserve visual functions. In this video, Professor Evgeny Alekseevich Egorov examines modern neuroprotection strategies, including innovative drug delivery methods and proven retinolamine and mexidol application schemes, which can significantly improve the prognosis for patients.

Main topics:

• Glaucoma today: a disease characterized by an increase in intraocular pressure beyond the tolerable level, which leads to glaucomatous optic neuropathy, optic atrophy and visual field defects. The main goal of treatment is to preserve visual functions and the patient's quality of life.
• The role of neuroprotection: reducing intraocular pressure does not guarantee stabilization of the glaucoma process. Complex therapy is necessary, including direct and indirect neuroprotection.
• Data on the clinical efficacy of neuroprotective therapy for glaucoma: when using the drug Mexidol , improvement in visual acuity, expansion of visual fields and improvement in electrophysiological parameters have been proven.

Clinical recommendations: Mexidol (ethylmethylhydroxypyridine succinate) is included in the therapy for primary open-angle and closed-angle glaucoma.

Key findings:

• Neuroprotection is an essential component of glaucoma treatment, especially when intraocular pressure is normalized.
• The use of neuroprotective therapy demonstrates stable positive results.
• Modern methods of drug delivery increase the effectiveness of therapy.

For whom: ophthalmologists, neurologists, general practitioners.

Practical value: The video provides treatment algorithms based on clinical guidelines and evidence, making it useful for the daily work of physicians.

This material is especially relevant for specialists working with patients with progressive glaucoma and looking for effective methods of preserving visual functions.

Announcement:

Arterial hypertension is not just a problem of high blood pressure, but a systemic disease that affects the blood vessels of the brain and leads to cognitive impairment. In this video, experts in the field of neurology and cardiology - Anatoly Ivanovich Fedin and Veronika Nikolaevna Shishkova - analyze the mechanisms of brain damage in hypertension, methods of early diagnosis and evidence-based approaches to neuroprotective therapy.

Main topics:

• Epidemiology and relevance:

—  44% of the adult population of Russia suffers from hypertension, but only a quarter achieve target blood pressure values.

—  Hypertension is the leading risk factor for stroke and vascular dementia in almost half of cases.

• Pathogenesis of brain damage:

—  Chronic ischemia due to small vessel microangiopathy.

—  Lacunar infarctions in the deep parts of the brain (shown on MRI).

—  Impaired autoregulation of cerebral blood flow and hypoxic cascade.

• Clinical manifestations:

—  Early symptoms: decreased concentration, “operational forgetfulness”, slowness of thinking.

—  Progression to frontal dysfunction (impaired planning, rigidity).

—  Association with asthenia, anxiety and depression.

• Diagnostics:

—  Screening: Mini-COG test, Montreal scale (MoCA).

—  Assessment of endothelial dysfunction and oxidative stress markers.

• Therapy:

o  Basic treatment of hypertension:

• Cautious reduction of pressure in patients with critical carotid artery stenosis.
• Target values: 130–140/80 mmHg for the elderly.

• Neuroprotection:

o  Mexidol (ethylmethylhydroxypyridine succinate):

Antioxidant and antihypoxant action.

• Scheme: 500 mg/day intravenously for 14 days → 250 mg × 3 times a day for 2 months.
• Results: improved cognitive functions, reduced asthenia.
• Clinical recommendations: included in the treatment of vascular cognitive impairment.

Key findings:

• Cognitive impairment in hypertension is not an “age-related norm”, but a consequence of cerebral microangiopathy.
• Screening with Mini-COG is mandatory for patients with blood pressure >140/90.
• The combination of antihypertensive therapy and Mexidol significantly improves the prognosis.

For whom: therapists, cardiologists, neurologists, general practitioners.

Practical value:

The video provides diagnostic and treatment algorithms based on evidence-based medicine. Particular attention is paid to patients with resistant hypertension and high risk of dementia.

Recommendation:

This material is a must-read for doctors working with older patients and striving to maintain not only physical but also cognitive health.

Announcement:

In this episode of the program "Neurology Plus", experts Anatoly Ivanovich Fedin and Elen Araikovna Mkhitaryan discuss one of the most pressing topics in modern medicine - a fragile patient with cerebrovascular disease and senile asthenia.

• Demography and Aging

By 2050, more than 30% of Russia's population will be over 65. This requires a revision of treatment approaches, since elderly patients often suffer from multiple chronic diseases at the same time.

• What is frailty?

This is a syndrome associated with age-related decline in the body's reserves. Its key symptoms are weakness, unintentional weight loss, sluggishness and low physical activity.

• The relationship between asthenia and stroke

In patients with senile asthenia, stroke is more severe and recovery is slower. Even "silent" lacunar infarctions can lead to complications.

• The dangers of orthostatic hypotension

A sharp drop in blood pressure when standing up is not just dizziness, but a serious marker of fragility and a risk factor for dementia.

• How to treat fragile patients?

Therapy should be cautious:

• Blood pressure does not always need to be reduced to “young” norms.
• Statins and aspirin are not suitable for primary prevention for everyone.
• The drug Mexidol has proven effective in improving cognitive functions and has demonstrated a high safety profile

Prevention: physical activity and cognitive reserve.

Dancing, learning, and social activity help keep your brain healthy. Even simple exercises can reduce the risk of dementia.

This broadcast will be especially useful for neurologists, therapists, geriatricians and anyone who works with elderly patients. Experts will discuss not only the theory, but also the practical aspects of managing complex cases.

The main conclusion: Fragility is not a death sentence. Competent therapy and prevention can significantly improve the quality of life of older people.

Announcement:

In the lecture “Polymorphism of clinical manifestations of chronic cerebral ischemia (CCI)”, Professor Anna Nikolaevna Bogolepova examines in detail the key aspects of diagnosis and treatment of this common condition.

What is HIM?

Chronic cerebral ischemia is a progressive disorder of the brain due to a long-term lack of blood supply. It is not an independent disease, but occurs as a complication of hypertension, atherosclerosis, diabetes and other cardiovascular pathologies. With age, its frequency increases sharply: after 80 years, leukoaraiosis (damage to the white matter) occurs in 95% of people.

Main symptoms

• Cognitive impairment (75% of cases): slow thinking, memory problems, decreased concentration.
• Asthenia is fatigue that does not go away after rest, often the first sign of chronic cerebral palsy.
• Movement disorders: unsteadiness of gait, parkinsonism, pseudobulbar syndrome (dysphagia, forced laughter/crying).
• Emotional disorders: depression (60% of patients), apathy, anxiety.

Diagnostics and differentiation

• Vascular dementia is diagnosed when daily activities are impaired due to cognitive deficits.
• It is important to distinguish vascular parkinsonism from Parkinson's disease: symmetry of symptoms, low effectiveness of levodopa.

Modern approaches to treatment

• • Correction of risk factors: control of blood pressure, sugar levels, quitting smoking.

• Non-drug methods:

• Cognitive training (crosswords, language learning).
• Physical activity (dancing, walking) improves blood supply to the brain.

• Drug therapy:

• Mexidol (ethylmethylhydroxypyridine succinate) has been proven to improve cognitive functions, reduce asthenia and anxiety.
• Optimal regimen: 2 weeks of injections + transition to Mexidol Forte tablets 250 mg 3 times a day.

Clinical recommendations

The Clinical Guidelines “Cognitive Disorders in the Elderly and Older Adults” emphasize the importance of pathogenetic therapy and an individual approach, especially in elderly patients.

Conclusion: CIM is a multifactorial disease that requires complex treatment. Early diagnosis and proper therapy can significantly improve the quality of life of patients.

Who is this video for?

Neurologists, therapists, geriatricians and anyone who works with patients with vascular cognitive impairment.

Announcement:

In this episode of the program "Interdisciplinary Academy. Neurology" experts in the field of neurology and cardiology - Evgeniya Viktorovna Yekusheva and Vadim Vitalievich Tyrenko - discuss a relevant topic: management of patients with cerebrovascular diseases (CVD) against the background of metabolic syndrome and diabetes mellitus.

Metabolic syndrome: a global problem

• Every fifth Russian has prediabetes, every twentieth has type 2 diabetes.
• Obesity is a key component of the syndrome, triggering systemic inflammation and insulin resistance.
• Patients with metabolic syndrome have a three-fold higher risk of cardiovascular events and an increased likelihood of dementia.

How does metabolic syndrome affect the brain?

• Early changes: atrophy of the frontal and temporal lobes, decreased cognitive functions.
• Chronic ischemia: microangiopathy, lacunar infarctions, leukoaraiosis.
• Systemic inflammation accelerates neurodegenerative processes.

Diagnostics and therapy

•  Metabolic syndrome criteria: abdominal obesity + 2 of:

• High blood pressure,
• High triglycerides,
• Low HDL,
• Hyperglycemia.

Treatment:

• Correction of risk factors (diet, physical activity).
• Drugs: metformin, statins, SGLT-2 inhibitors.
• Neuroprotection: Mexidol reduces oxidative stress, improves cognitive functions.

Mexidol: proven effectiveness

• Mechanism of action: antioxidant, antihypoxant.
• Research:

• Improving memory and attention in patients with CCI.
• Reduction in the level of proinflammatory cytokines (TNF-α, IL-6).

• Dosage regimen: sequential administration regimen: 2 weeks of injections → 2 months of tablets (250 mg × 3 times/day).

Why do doctors miss brain damage?

• Patients rarely complain of early cognitive impairment.
• Therapists often focus on cardiovascular risks rather than neurological consequences.
• Solution: Active screening for cognitive impairment in patients with diabetes and obesity.

Key takeaway:

Metabolic syndrome is not only obesity and hypertension, but also a high risk of brain damage. Complex therapy, including neuroprotectors (the drug Mexidol), can slow the progression of cognitive impairment.

Who is this video for?

Neurologists, therapists, endocrinologists, cardiologists - everyone who works with patients with metabolic disorders and cerebrovascular diseases.